BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has launched ORTHOVISC® mini in the European Union. ORTHOVISC mini is a smaller dosage indication of ORTHOVISC®, which has been marketed in Europe since 1996 and is used mainly for treatment of osteoarthritis of the knee. The Company is also initiating a post-approval clinical study of ORTHOVISC mini to gain additional clinical experience with regional opinion leaders who specialize in the treatment of osteoarthritis in small joints.
